ACL Digital Life Sciences Tackled Diversity and Data Bias To Elevate RWE Quality in the Medical Device Sector
Overview
A market leader in medical devices—responsible for more than 5.4 million treatments and impacting over 150,000 patients—sought to enhance the validity of its real-world evidence (RWE) data. Its technology is indicated for treating major depressive disorder (MDD) and comorbid anxiety symptoms in adult patients. However, limited patient diversity and methodological inconsistencies in RWE studies posed challenges to deriving broad, actionable clinical insights. The company partnered with ACL Digital Life Sciences to overcome these limitations and build a more robust and reliable evidence framework.
Download Case Study
Challenges
Despite its leadership in the medical device market, the customer faced critical challenges in leveraging RWE to support broader clinical claims:
Limited patient diversity in existing RWE data restricted the generalizability of study outcomes
The observational nature of real-world studies introduced potential bias
Inconsistencies and data errors compromised the reliability of findings
Difficulty integrating RWE with clinical trial data impeded comprehensive analysis
Insufficient transparency in reporting key methodological decisions reduced trust and the interpretability of the results
Solution
- Expanded inclusion criteria to reflect a more diverse patient population, collaborating with varied healthcare settings.
- Applied advanced statistical techniques to mitigate bias from observational data sources. Ensured consistency in study endpoints and data collection methods
- Instituted rigorous quality assurance protocols to minimize inconsistencies and improve data integrity.
- Developed standardized integration protocols to harmonize real-world data with clinical trial results.
- Ensured transparent reporting by pre-registering study protocols, documenting all deviations, and adhering to best-practice guidelines.
Outcomes
Through its partnership with ACL Digital Life Sciences, the client realized measurable and strategic benefits:
- Achieved greater inclusivity in RWE studies, enabling more representative conclusions for broader patient populations
- Enhanced credibility and reliability by reporting limitations thus enabling impartial interpretations
- Collaborated with data experts and adhered to strict standards
- Established a transparent, replicable RWE methodology, aligning with regulatory and industry standards
- Built a foundation for integrating RWE with traditional clinical trial data, unlocking deeper insights into treatment efficacy and patient outcomes
